Related references
Note: Only part of the references are listed.Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis
Matthijs C. Brouwer et al.
ACTA NEUROPATHOLOGICA (2014)
Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis
Madelijn Geldhoff et al.
IMMUNOGENETICS (2013)
Characterization of a pneumococcal meningitis mouse model
Barry Mook-Kanamori et al.
BMC INFECTIOUS DISEASES (2012)
Hearing loss in adults surviving pneumococcal meningitis is associated with otitis and pneumococcal serotype
S. G. B. Heckenberg et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Genetic variation in GLCCI1 and dexamethasone in bacterial meningitis
Matthijs C. Brouwer et al.
JOURNAL OF INFECTION (2012)
Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis
Paul Y. Kim et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)
Cerebral Infarction in Adults with Bacterial Meningitis
Ewout S. Schut et al.
NEUROCRITICAL CARE (2012)
Intracerebral Hemorrhages in Adults with Community Associated Bacterial Meningitis in Adults: Should We Reconsider Anticoagulant Therapy?
Barry B. Mook-Kanamori et al.
PLOS ONE (2012)
Pathogenesis and Pathophysiology of Pneumococcal Meningitis
Barry B. Mook-Kanamori et al.
CLINICAL MICROBIOLOGY REVIEWS (2011)
Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis
Bianca Woehrl et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Thrombin-activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis
M. Valls Seron et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis
Matthijs C. Brouwer et al.
LANCET INFECTIOUS DISEASES (2010)
Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children
M. EMONTS et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study
E. L. E. de Bruijne et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research
Pauline F. Marx et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2009)
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia
Evelien Heylen et al.
THROMBOSIS RESEARCH (2009)
Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome
Dolors Tassies et al.
THROMBOSIS RESEARCH (2009)
Gender Differences in Genetic Risk Profiles for Cardiovascular Disease
Kaisa Silander et al.
PLOS ONE (2008)
TAFI and PAI-1 levels in human sepsis
Sacha Zeerleder et al.
THROMBOSIS RESEARCH (2006)
Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice
R Renckens et al.
JOURNAL OF IMMUNOLOGY (2005)
Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation
CC Chen et al.
ANNALS OF HEMATOLOGY (2005)
Evolution of thrombin formation and fibrinolysis markers, including thrombin activatable fibrinolysis inhibitor, during severe meningococcemia
M Fouassier et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2005)
A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease
JAK Hovinga et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Clinical features and prognostic factors in adults with bacterial meningitis
D van de Beek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor
EAT Velde et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Cognitive impairment in adults with good recovery after bacterial meningitis
D van de Beek et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
M Schneider et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N
WD Campbell et al.
MICROBIOLOGY AND IMMUNOLOGY (2002)
Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation
R Watanabe et al.
THROMBOSIS RESEARCH (2001)
Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene:: evidence that plasma TAFI antigen levels are strongly genetically controlled
M Henry et al.
BLOOD (2001)
Share Paper
